A Phase II Study of Atezolizumab Immunotherapy in Persistent or Recurrent Hodgkin Lymphoma

Full Title

A Phase II Study of Atezolizumab in Relapsed or Refractory Hodgkin Lymphoma


The purpose of this study is to assess the safety and effectiveness of the immunotherapy drug atezolizumab in patients with Hodgkin lymphoma that has continued to grow or came back despite prior therapy. Atezolizumab is designed to improve the immune system’s ability to recognize and destroy cancer cells by blocking PD-L1, a protein made by some cancers. It is approved for treating bladder and lung cancers; its use in this study is considered investigational. Atezolizumab is given intravenously (by vein).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have Hodgkin lymphoma that continues to grow or came back despite at least two prior regimens that included brentuximab vedotin.
  • Patients must have disease that persists despite a stem cell transplant or must be ineligible for autologous stem cell transplantation.
  • At least 3 weeks must pass between the completion of previous treatment and entry into the study.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Anas Younes at 212-639-5059.





Disease Status

Relapsed or Refractory